At In the Pipeline, Derek Lowe asks in which fields people would consider starting a small drug company. He writes that oncology would have been a good choice a decade ago and that going into cardiovascular disease and metabolic disorders doesn’t make much sense, unless you've been sitting on a golden egg. Alzheimer's disease, he says, is an under-served market, adding that "it's unserved for a lot of damned good reasons. The same goes for a number of other CNS indications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.